文献速递银屑病与炎症性皮肤病

Bimekizumab治疗中重度斑块状银屑病疗效持久性达196周及安全性达4年:BE BRIGHT开放标签扩展试验结果

Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
PubMed 文献 · J Am Acad Dermatol · 2025-04-24

该研究汇总3项III期试验及其开放标签扩展BE BRIGHT的数据,评估bimekizumab治疗中重度斑块状银屑病的4年疗效与安全性。结果显示,从基线持续接受bimekizumab治疗的患者中,第52周76.2%达到PASI 100,第196周仍有64.7%维持完全皮损清除;4年治疗中出现的不良事件率为169.8/100患者年,未随暴露时间延长而增加,常见不良事件为鼻咽炎、口腔念珠菌病和上呼吸道感染,与已知安全性特征一致。

要点

  • 持续bimekizumab治疗第52周76.2%患者达到PASI 100,第196周64.7%维持完全清除。
  • 4年治疗中出现的不良事件率为169.8/100患者年,未见随暴露延长而升高。
  • 常见不良事件为鼻咽炎、口腔念珠菌病和上呼吸道感染,与已知安全性一致。

核心结论

  • 近三分之二接受bimekizumab治疗的患者在4年内达到并维持完全皮损清除,支持其作为有效、快速且持久的长期治疗选择。

研究设计与样本

  • 汇总3项III期试验(BE VIVID、BE READY、BE SURE)及其开放标签扩展(OLE;BE BRIGHT)的数据。

主要发现

  • 从基线持续接受bimekizumab治疗的患者中,第52周76.2%达到PASI 100(基线PASI评分改善100%)。
  • 第196周时,64.7%的患者维持PASI 100。
  • 4年治疗中出现的不良事件率为169.8/100患者年(N=1495),未随暴露时间延长而增加。
  • 最常见的治疗中出现的不良事件为鼻咽炎、口腔念珠菌病和上呼吸道感染,与bimekizumab已知安全性特征一致。

临床怎么用

  • 对于中重度斑块状银屑病,bimekizumab可持续维持完全皮损清除长达4年,支持其作为长期管理选择。
  • 长期治疗中需关注鼻咽炎、口腔念珠菌病和上呼吸道感染等常见不良事件,但整体安全性未随暴露延长而增加。

局限性

  • eligibility criteria and ethnic representation(入组标准与种族代表性限制)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. OBJECTIVE: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. METHODS: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received ≥1 bimekizumab dose. RESULTS: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64.7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. LIMITATIONS: Eligibility criteria and ethnic representation. CONCLUSION: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Langley RG, Lebwohl M, et al. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025. PMID: 40286813. doi:10.1016/j.jaad.2025.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。